​PHARMARESEARCH establishes Partnership with Laboratoires VIVACY for Distribution of REJURAN in Europe 

Secures Strategic Distribution Network Across 22 European Countries, Including Key Markets Such as the UK, Germany, and France

PharmaResearch (CEO: Jihoon Sohn), a leading regenerative medicine company, announced today the signing of a strategic partnership agreement with VIVACY,

a France-based global medical aesthetics company, to distribute its medical device brand Rejuran in the European market.

VIVACY, headquartered in France, is one of the leading company’s in the European medical aesthetics industry. With subsidiaries and branch offices across key cities in Europe, VIVACY has built a robust commercial and marketing network.

Through this strategic partnership, PharmaResearch aims to combine VIVACY’s vast distribution network along with their expertise in the market to accelerate their brand’s entry and presence in Europe.

The agreement is valued at approximately EUR 54.5 million over 5 years and spans to 22 countries, including the major Western European markets (United Kingdom, Germany, France, Italy, and Spain).

PharmaResearch plans to start distributing in the key European countries within this year, followed by a phased rollout across the region.

Jihoon Sohn, CEO of PharmaResearch, commented that

“Rejuran is currently the only PN (Polynucleotide)-based medical device approved under the EU Medical Device Regulation (MDR). We are confident that we will increase Rejuran’s global visibility and strengthen its position as a leading skin booster brand in the international medical aesthetics market through this partnership”